Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02526017 · ClinicalTrials.gov registry record · Phase 1

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

A Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, sponsored by Five Prime Therapeutics.

Completed
Registry status
Phase 1
Development phase
313
Enrollment target
20
Study locations

NCT02526017 is a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer that has completed, run by Five Prime Therapeutics. The registered enrollment target is 313 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02526017, a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, has completed, sponsored by Five Prime Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
313 participants
Enrollment target
20
Study locations

Study Summary

Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.

Conditions Studied

Non-Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Head and Neck Cancer Advanced Solid Tumors Renal Cell Carcinoma Malignant Glioma

Interventions

  • BIOLOGICAL Nivolumab
  • BIOLOGICAL Cabiralizumab

Study Locations (20)

California

  • Moores UC San Diego Cancer Center - La Jolla
  • Norris Comprehensive Cancer Center, University of Southern California - Los Angeles
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Center - Los Angeles
  • UC Davis Comprehensive Cancer Center - Sacramento
  • University of California, San Francisco - San Francisco
  • Sarcoma Oncology Research Center - Santa Monica
  • UCLA Hematology/Oncology- Santa Monica - Santa Monica

Florida

  • Mount Sinai Comprehensive Cancer Center - Miami Beach
  • H. Lee Moffitt Cancer Center and Research Institute - Tampa

Illinois

  • Rush University Medical Center - Chicago
  • University of Chicago Medical Center - Chicago

Michigan

  • Karmanos Cancer Institute - Detroit
  • Henry Ford Hospital - Detroit

Arizona

  • Scottsdale Healthcare Hospitals DBA Honor Health - Scottsdale

Georgia

  • Emory University Hospital - Atlanta

Indiana

  • Indiana University Health Hospital - Indianapolis

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

Trial Details

FieldValue
Enrollment Target 313 participants
Start Date 2015-09-08
Est. Completion 2019-11-18
Phase Phase 1

Sponsor

Five Prime Therapeutics

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02526017

The ClinicalTrials.gov registry entry for NCT02526017 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 313 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (52% lower). The listed sponsor is Five Prime Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.

NCT02526017 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT02526017 about?

NCT02526017 is a clinical study titled "Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers". Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.

What is the current status of trial NCT02526017?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 313 participants. The study started on 2015-09-08. Estimated completion is 2019-11-18.

What conditions does trial NCT02526017 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, Advanced Solid Tumors.

What interventions are being tested in trial NCT02526017?

The interventions under investigation include: Nivolumab (BIOLOGICAL), Cabiralizumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02526017?

This trial is sponsored by Five Prime Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02526017 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Ovarian Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.